For rare disease patients in Mainland China, hope of greater access to treatment
Clarivate
MAY 24, 2022
Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. Mainland China has taken significant steps toward improving access to treatment for its estimated 20 million rare disease patients in recent years. [1]
Let's personalize your content